ProCE Banner Activity

EV-101: Updated Results From Phase I Study of Enfortumab Vedotin in Patients With Metastatic Urothelial Cancer

Slideset Download
Conference Coverage
Enfortumab vedotin, an investigational antibody-drug conjugate, appears well tolerated in this phase I study with an ORR of 41% in previously treated patients with mUC.

Released: June 08, 2018

Expiration: June 07, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen